mepitiostane and Neoplasm-Metastasis

mepitiostane has been researched along with Neoplasm-Metastasis* in 1 studies

Trials

1 trial(s) available for mepitiostane and Neoplasm-Metastasis

Article	Year
2alpha, 3alpha-epithio-5alpha-androstan-17beta-yl 1-methoxycyclopentyl ether in the treatment of advanced breast cancer: Japanese Cooperative Group of Hormonal Treatment for Breast Cancer. Cancer, 1978, Volume: 41, Issue:2 A new antiestrogenic steroid, 2alpha, 3alpha-epithio-5alpha-androstand-17beta-yl 1-methoxy-cyclopentyl ether, mepitiostane, given orally 10 mg b.i.d. to 50 patients with advanced breast cancer, produced objective regression of the tumor in 17 cases (34%). Objective regression of the metastases was seen in 20 of the 48 control patients given fluoxymesterone, 10 mg b.i.d. orally (47.7%). These figures do not differ significantly. The study was a prospective, randomized, double-blind trial employing the protocol of the Cooperative Breast Cancer Group. There was a significantly lower incidence of hepatotoxicity in the patients given mepitiostane. Topics: Administration, Oral; Age Factors; Androstanes; Androstanols; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Estrogen Antagonists; Female; Fluoxymesterone; Humans; Liver; Menopause; Middle Aged; Neoplasm Metastasis; Remission, Spontaneous; Sulfides	1978

Article

Year

2alpha, 3alpha-epithio-5alpha-androstan-17beta-yl 1-methoxycyclopentyl ether in the treatment of advanced breast cancer: Japanese Cooperative Group of Hormonal Treatment for Breast Cancer.

Cancer, 1978, Volume: 41, Issue:2

A new antiestrogenic steroid, 2alpha, 3alpha-epithio-5alpha-androstand-17beta-yl 1-methoxy-cyclopentyl ether, mepitiostane, given orally 10 mg b.i.d. to 50 patients with advanced breast cancer, produced objective regression of the tumor in 17 cases (34%). Objective regression of the metastases was seen in 20 of the 48 control patients given fluoxymesterone, 10 mg b.i.d. orally (47.7%). These figures do not differ significantly. The study was a prospective, randomized, double-blind trial employing the protocol of the Cooperative Breast Cancer Group. There was a significantly lower incidence of hepatotoxicity in the patients given mepitiostane.

Topics: Administration, Oral; Age Factors; Androstanes; Androstanols; Breast Neoplasms; Clinical Trials as Topic; Double-Blind Method; Estrogen Antagonists; Female; Fluoxymesterone; Humans; Liver; Menopause; Middle Aged; Neoplasm Metastasis; Remission, Spontaneous; Sulfides

1978